AKT1 and acute lymphoblastic leukemia: At the level of PI3Ks, several pan-PI3K class I inhibitors (LY924002 and NVP-BKM120) showed anti-leukemic effects in T-ALL cell lines and primary patient samples having hyperactivation of PI3K/AKT pathway [103,104].